These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 28383392)

  • 1. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
    Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
    Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
    Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients.
    Cochrane AB
    Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S17-21. PubMed ID: 16990640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients.
    Villeneuve D; Brothers A; Harvey E; Kemna M; Law Y; Nemeth T; Gantt S
    Pediatr Transplant; 2013 Feb; 17(1):80-5. PubMed ID: 23240598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
    Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Vernooij RW; Michael M; Ladhani M; Webster AC; Strippoli GF; Craig JC; Hodson EM
    Cochrane Database Syst Rev; 2024 May; 5(5):CD003774. PubMed ID: 38700045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
    Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
    Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis.
    Wong DD; van Zuylen WJ; Novos T; Stocker S; Reuter SE; Au J; Foster CSP; Day RO; Horvath AR; Endre Z; Rawlinson WD
    Microbiol Spectr; 2022 Jun; 10(3):e0268421. PubMed ID: 35658598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
    Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
    BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of a Weight-based Dosing Regimen of Valganciclovir for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients.
    Pappo A; Peled O; Berkovitch M; Bilavsky E; Rom E; Amir J; Krause I; Yarden-Bilavsky H; Scheuerman O; Ashkenazi-Hoffnung L
    Transplantation; 2019 Aug; 103(8):1730-1735. PubMed ID: 31343571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days.
    Welker H; Farhan M; Humar A; Washington C
    Transplantation; 2010 Dec; 90(12):1414-9. PubMed ID: 21076372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
    Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
    Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
    Oppenheimer F; Gonzalez-Molina M; Rubio M
    Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.
    Lapidus-Krol E; Shapiro R; Amir J; Davidovits M; Steinberg R; Mor E; Avitzur Y
    Pediatr Transplant; 2010 Sep; 14(6):753-60. PubMed ID: 20477976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
    Liverman R; Serluco A; Nance G; George R; Rodriguez DS; Deshpande S; Mao C; Garro R; Yildirim I
    Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
    Paya C; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Pescovitz MD;
    Am J Transplant; 2004 Apr; 4(4):611-20. PubMed ID: 15023154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM; Lake KD; Arenas JD; Fontana RJ
    Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients.
    Shaikh S; Jasiak-Panek N; Park JM
    Clin Transplant; 2018 Sep; 32(9):e13369. PubMed ID: 30076649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
    Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
    J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.